Literature DB >> 2321753

DESIGN: computerized optimization of experimental design for estimating Kd and Bmax in ligand binding experiments. II. Simultaneous analysis of homologous and heterologous competition curves and analysis blocking and of "multiligand" dose-response surfaces.

G E Rovati1, D Rodbard, P J Munson.   

Abstract

We have developed a computer program, DESIGN, for optimization of ligand binding experiments to minimize the "average" uncertainty in all unknown parameters. An earlier report [G. E. Rovati, D. Rodbard, and P. J. Munson (1988) Anal. Biochem. 174, 636-649] described the application of this program to experiments involving a single homologous or heterologous dose-response curve. We now present several advanced features of the program DESIGN, including simultaneous optimization of two or more binding competition curves optimization of a "multiligand" experiment. Multiligand designs are those which use combinations of two (or more) ligands in each reaction tube. Such designs are an important and natural extension of the popular method of "blocking experiments" where an additional ligand is used to suppress one or more classes of sites. Extending the idea of a dose-response curve, the most general multiligand design would result in a "dose-response surface". One can now optimize the design not only for a single binding curve, but also for families of curves and for binding surfaces. The examples presented in this report further demonstrate the power and utility of the program DESIGN and the nature of D-optimal designs in the context of more complex binding experiments. We illustrate D-optimal designs involving one radioligand and two unlabeled ligands; we consider one example of homogeneous and several examples of heterogeneous binding sites. Further, to demonstrate the virtues of the dose-response surface experiment, we have compared the optimal surface design to the equivalent design restricted to traditional dose-response curves. The use of DESIGN in conjunction with multiligand experiments can improve the efficiency of estimation of the binding parameters, potentially resulting in reduction of the number of observations needed to obtain a desired degree of precision in representative cases.

Mesh:

Substances:

Year:  1990        PMID: 2321753     DOI: 10.1016/0003-2697(90)90030-d

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  6 in total

1.  Simultaneous optimal experimental design for in vitro binding parameter estimation.

Authors:  C Steven Ernest; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-13       Impact factor: 2.745

2.  Experimental design and estimation of parameters in complex radioligand binding systems.

Authors:  C M Staschen; L D Homer
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

3.  Partial purification and characterization of Bacillus thuringiensis Cry1A toxin receptor A from Heliothis virescens and cloning of the corresponding cDNA.

Authors:  D I Oltean; A K Pullikuth; H K Lee; S S Gill
Journal:  Appl Environ Microbiol       Date:  1999-11       Impact factor: 4.792

4.  Optimal designs for pairwise calculation: An application to free energy perturbation in minimizing prediction variability.

Authors:  Qingyi Yang; Woodrow Burchett; Gregory S Steeno; Shuai Liu; Mingjun Yang; David L Mobley; Xinjun Hou
Journal:  J Comput Chem       Date:  2019-11-13       Impact factor: 3.376

5.  Comparison of toxin overlay and solid-phase binding assays to identify diverse CryIA(c) toxin-binding proteins in Heliothis virescens midgut.

Authors:  E A Cowles; H Yunovitz; J F Charles; S S Gill
Journal:  Appl Environ Microbiol       Date:  1995-07       Impact factor: 4.792

6.  Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: preliminary evidence for different binding domains.

Authors:  C M Dersch; H C Akunne; J S Partilla; G U Char; B R de Costa; K C Rice; F I Carroll; R B Rothman
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.